Rituxan Data In Patients With Rheumatoid Arthritis To Be Presented At The American College Of Rheumatology Annual Scientific Meeting

Genentech, Inc. (NYSE: DNA) and Biogen Idec, Inc. (Nasdaq: BIIB) announced that Rituxan^: (rituximab) data including results from Phase II and III studies of Rituxan in patients with moderately-to-severely active rheumatoid arthritis (RA) will be featured in two podium presentations and eight poster presentations at the American College of Rheumatology (ACR) Annual Scientific Meeting in San Francisco this week.